TY - JOUR T1 - An affordable anti-SARS-COV-2 spike protein ELISA test for early detection of IgG seroconversion suited for large-scale surveillance studies in low-income countries JF - medRxiv DO - 10.1101/2020.07.13.20152884 SP - 2020.07.13.20152884 AU - Renata G. F. Alvim AU - Tulio M. Lima AU - Danielle A. S. Rodrigues AU - Federico F. Marsili AU - Vicente B. T. Bozza AU - Luiza M. Higa AU - Fabio L. Monteiro AU - Daniel P. B. Abreu AU - Isabela C. Leitão AU - Renato S. Carvalho AU - Rafael M. Galliez AU - Terezinha M. P. P. Castineiras AU - Alberto Nobrega AU - Leonardo H. Travassos AU - Amilcar Tanuri AU - Orlando C. Ferreira, Jr. AU - André M. Vale AU - Leda R. Castilho Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/29/2020.07.13.20152884.abstract N2 - Background Accurate serological tests are essential tools to allow adequate monitoring and control of COVID-19 spread. Production of a low-cost and high-quality recombinant viral antigen can enable the development of reliable and affordable serological assays, which are urgently needed to facilitate epidemiological surveillance studies in low-income economies.Methods Trimeric SARS-COV-2 spike (S) protein was produced in serum-free, suspension-adapted HEK293 cells. Highly purified S protein was used to develop an ELISA, named S-UFRJ test. It was standardized to work with different types of samples: (i) plasma or serum from venous blood samples; (ii) eluates from dried blood spots (DBS) obtained by collecting blood drops from finger prick.Findings We developed a cost-effective, scalable technology to produce S protein based on its stable expression in HEK293 cells. Using this recombinant antigen we presented a workflow for test development in the setting of a pandemic, starting from limited amounts of samples up to reaching final validation with hundreds of samples. Test specificity was determined to be 98.6%, whereas sensitivity was 95% for samples collected 11 or more days after symptoms onset. A ROC analysis allowed optimizing the cut-off and confirming the high accuracy of the test. Endpoint titers were shown to correlate with virus neutralization assessed as PRNT90. There was excellent agreement between plasma and DBS samples, significantly simplifying sample collection, storing and shipping. An overall cost estimate revealed that final retail price could be in the range of one US dollar.Interpretation The S-UFRJ assay developed herein meets the quality requirements of high sensitivity and specificity. The low cost and the use of mailable DBS samples allow for serological surveillance of populations regardless of geographical and socio-economic aspects, with special relevance for public health policy actions in low-income countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by CTG,Senai DN/CETIQT, FAPERJ, CNPq, CAPES and Instituto Serrapilheira.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples collected at the State Hematology Institute Hemorio followed a protocol approved by the local ethics committee (CEP Hemorio; approval #4008095). Samples collected at UFRJ COVID Screening and Diagnostic Center followed a protocol approved by the national ethics committee (CONEP, Brazil; protocol #30161620000005257; approval #3953368): subjects were initially interviewed and, if they accepted to participate, they signed the informed consent, answered a questionnaire (addressing demographic data, onset and type of symptoms, history of travel abroad, among other information) and had blood (venous blood and/or finger prick) and nasopharyngeal swab collected. Only symptomatic subjects who presented at least two of the following symptoms were included: loss of taste or smell, fever, shortness of breath, diarrhea, headache, extreme tiredness, dry cough, sore throat, runny or stuffy nose, or muscle aches. Dried blood spots (DBS) were obtained by finger pricking with commercially available sterile lancets and lancing devices. Either plastic strips containing pads of filter paper, or 2.5 cm (W) x 7.5 cm (L) filter paper with three blood spots from the same volunteer, were used to collect whole blood from finger pricks.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data of all experiments are available upon request. ER -